ArticleCurrent oncology (Toronto, Ont.)2021

Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD).

Jennifer Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.